Procrit Injection, Solution
Product Images NDC 59676-340

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Procrit (NDC 59676-340). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Janssen Products, Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Procrit 01)

An instructional illustration showing medical supplies for injection, including a vial, a disposable syringe labeled with needle cover, syringe barrel with markings, and plunger rod, as well as alcohol wipes, a cotton ball, and a puncture-proof container with a biohazard symbol for safe disposal.*

FDA Label Image

Figure 2 (Procrit 02)

An instructional illustration showing the proper handwashing technique. The image depicts hands being rubbed together with soap and water dripping, emphasizing cleanliness.*

FDA Label Image

Figure 3 (Procrit 03)

Line drawing illustration showing a hand holding a vial, likely demonstrating how to hold the vial for administering an injection. The image contains no text or branding.*

FDA Label Image

Figure 4 (Procrit 04)

An instructional diagram showing a pair of hands preparing an injection vial. One hand holds a vial steady while the other hand removes a cap or seal from the top of the vial. This likely illustrates the initial step in preparing a PRIT (Erythropoietin) injection solution for administration.*

FDA Label Image

Figure 5 (Procrit 05)

An instructional illustration showing how to properly remove the cap of a syringe by pulling it straight off. The image includes two hands holding the syringe and cap, with an arrow indicating the direction to pull.*

FDA Label Image

Figure 6 (Procrit 06)

An instructional line drawing showing hands holding and preparing to use a syringe with a needle. One hand holds the syringe barrel, while the other hand holds the plunger, demonstrating the injection preparation technique. No specific product branding or text is visible.*

FDA Label Image

Figure 7 (Procrit 07)

An instructional line drawing showing a hand holding a vial and another hand using a syringe to draw liquid from the vial. A downward-pointing arrow above the syringe indicates the action of drawing the solution into the syringe.*

FDA Label Image

Figure 8 (Procrit 08)

An instructional black-and-white line drawing showing a hand holding a vial and drawing liquid into a syringe. The illustration depicts how to prepare an injection solution for administration.*

FDA Label Image

Figure 9 (Procrit 09)

An instructional illustration depicting a hand holding a syringe labeled with parts 'needle' and 'plunger.' The image demonstrates proper grip and usage of the syringe plunger, likely for administering an injection.*

FDA Label Image

Figure 10 (Procrit 10)

An instructional line drawing showing two hands preparing a syringe for injection. The top hand is holding the needle end of the syringe, while the bottom hand is holding the plunger, with arrows indicating the direction to push the plunger. The labels "NEEDLE" and "PLUNGER" identify these parts of the syringe.*

FDA Label Image

Figure 11 (Procrit 11)

An instructional diagram showing recommended injection sites on the human body for a medication. The front view highlights areas on the upper arms, abdomen, and thighs, while the back view highlights upper arms and buttocks, indicating appropriate locations for subcutaneous or intravenous injections.*

FDA Label Image

Figure 12 (Procrit 12)

An instructional illustration showing a hand pinching the skin on a bent knee, likely demonstrating the technique for subcutaneous injection administration.*

FDA Label Image

Figure 13 (Procrit 13)

An instructional illustration showing a hand resting on the front thigh above the knee, likely demonstrating the recommended injection site for a subcutaneous or intramuscular injection in the thigh area.*

FDA Label Image

Figure 14 (Procrit 14)

An instructional diagram showing proper injection angles for administration, depicting a hand holding a syringe inserted into the thigh at 45-degree and 90-degree angles.*

FDA Label Image

Figure 15 (Procrit 15)

Illustration showing fingers holding a small rectangular object positioned above a cylindrical medical device, likely depicting an instructional step involving attaching or handling a component related to an injection or infusion setup.*

FDA Label Image

Figure 16 (Procrit 16)

An illustration showing a syringe needle inserted into a vial or container, connected to intravenous tubing. The image represents the process of preparing or administering an injectable solution, relevant to intravenous or subcutaneous drug delivery.*

FDA Label Image

Principal Display Panel (2,000 Unit Vial Carton)

PRIT Epoetin Alfa 2,000 Units/mL injection solution packaging label. The label indicates it is for intravenous or subcutaneous use, sterile with no preservative. The labeler is Janssen Products, LP. The label includes usage instructions, storage conditions, barcode, lot and expiration placeholders, and tamper-evident areas.*

FDA Label Image

Principal Display Panel (3,000 Unit Vial Carton)

PRIT 3,000 Units/mL injection solution carton label featuring Epoetin Alfa as the active ingredient for intravenous or subcutaneous use. The label includes dosage strength prominently along the sides, directions to discard unused portions of 1 mL single-dose vials, and storage instructions to refrigerate between 2°C to 8°C. Janssen Products, LP is identified as the labeler.*

FDA Label Image

Principal Display Panel (4,000 Unit Vial Carton)

Packaging label for PRIT Erythropoietin Alfa Injection, Solution, 4,000 Units/mL by Janssen Products, LP. The label indicates 6 single-dose 1 mL vials, for intravenous or subcutaneous use, sterile solution with no preservative. Storage instructions and pharmacist label placement area are included along with barcodes and tamper-evident areas.*

FDA Label Image

Principal Display Panel (10,000 Unit Vial Carton)

Packaging label for PRIT injection, solution containing Epoetin Alfa 10,000 Units/mL. The label indicates single-dose 1 mL vials with 6 vials per package, for intravenous or subcutaneous use. The labeler is Janssen Products, LP, with storage instructions and barcode displayed. The label features prominent red and white color blocks with product information and pharmacist label area.*

FDA Label Image

Principal Display Panel (40,000 Unit Vial Carton)

Label for PRIT Epoetin Alfa injection solution, 40,000 Units/mL, by Janssen Products, LP. The label indicates a sterile, preservative-free solution for intravenous or subcutaneous use, supplied in 4 x 1 mL single-dose vials. It includes storage instructions, dosage caution, and a pharmacist label area. The NDC number 59676-340-01 is shown.*

FDA Label Image

Principal Display Panel (20,000 Units/2 mL Vial Carton)

PRIT 20,000 Units/2 mL (10,000 Units/mL) multiple-dose vials packaging label for injection solution. The label states it is a sterile solution preserved at 10,000 Units/mL for intravenous or subcutaneous use only. The label includes the Janssen Products, LP manufacturer information and features usage instructions, storage conditions at 2° to 8°C, and tamper-evident areas. The package size is 2 mL vials, Rx only.*

FDA Label Image

Principal Display Panel (20,000 Unit Vial Carton)

Packaging label for PRIT Epoetin Alfa 20,000 Units/mL injection solution. The label indicates multiple-dose vials of 1 mL each for intravenous or subcutaneous use, distributed by Janssen Products, LP. The label includes storage instructions, lot and expiration placeholders, a barcode, and a warning about requiring a medication guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.